IART (Integra Lifesciences Holdings) Momentum Rank: 9 (As of Aug. 24, 2026) — 29% Above Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

IART Integra Lifesciences Holdings Corp IART
70 GF Score
Price $16.69
GF Value $20.52
Valuation Modestly Undervalued
! 8 Warning Signs
View Full Analysis

What is Integra Lifesciences Holdings Momentum Rank?

Integra Lifesciences Holdings IART -0.33% 70 Momentum Rank is 9 as of Aug. 24, 2026, which is 29% above its 10-year median of 7.00. GuruFocus rates IART with a GF Score™ of 70/100 and a GF Value™ of $20.52 (Modestly Undervalued). The stock has 8 warning signs investors should review.

Integra Lifesciences Holdings has the Momentum Rank of 9.

Momentum Rank measures the strength and persistence of a stock's price movement over time, rated on a scale of 1 to 10.

For Momentum Rank, we considered the residual momentum concept that was widely studied by Blitz and his colleagues as well as by Nobel Prize laureates Fama and French. However, we did not find any significant differences in the performances of stocks with different ranks of residual momentum. Therefore, we use traditional momentum instead.

Momentum Rank is determined using the standardized momentum ratio and other momentum indicators. The standardized momentum ratio is the average of the performances from 12 months ago to 1 month ago and 6 months ago to 1 month ago, divided by the beta of the stock over the past 12 months. To calculate the momentum ratio today, we would use the average of the two performance numbers.

For momentum, we found that stock price performance does not have a monotonic correlation with the momentum ratio. The stocks with the highest momentum ratios perform worse than those at about the 70th percentile. Therefore, for the momentum rank, we ranked the stocks at about the 70th percentile of the momentum ratio as the highest at 10.

A higher score reflects strong price momentum and indicates greater potential for superior performance. Conversely, a lower score indicates that momentum is either too high or too low, and stocks tend to underperform.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Integra Lifesciences Holdings Momentum Rank Related Terms

IART vs ENOV, AHCO, INSP: Momentum Rank Comparison

For the Medical Devices subindustry, Integra Lifesciences Holdings's Momentum Rank, along with its competitors' market caps and Momentum Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Integra Lifesciences Holdings Momentum Rank vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Integra Lifesciences Holdings's Momentum Rank distribution charts can be found below:

* The bar in red indicates where Integra Lifesciences Holdings's Momentum Rank falls into.


IART
70GF Score
Integra Lifesciences Holdings Corp IART
Momentum Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Momentum Rank →
What does a Momentum Rank of 9 mean?
Integra Lifesciences Holdings (IART) has a Momentum Rank of 9 as of Aug. 24, 2026. Momentum Rank is determined using the standardized momentum ratio, measuring the speed and velocity of price changes in a stock. View historical data on Integra Lifesciences Holdings and its competitors. This is 29% above median its historical median of 7.00. Over the past decade, Integra Lifesciences Holdings' Momentum Rank has ranged from 2.00 to 10.00.
Is Integra Lifesciences Holdings' Momentum Rank too high?
Integra Lifesciences Holdings' current Momentum Rank of 9 is 29% above median its 10-year median of 7.00. Over the past 10 years, this metric has ranged from a low of 2.00 to a high of 10.00. Overall, Integra Lifesciences Holdings has a GF Score™ of 70/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Integra Lifesciences Holdings' Momentum Rank compare to ENOV and AHCO?
Integra Lifesciences Holdings' Momentum Rank of 9 can be compared against companies in the Medical Devices & Instruments industry. Historically, Integra Lifesciences Holdings' own Momentum Rank has ranged from 2.00 to 10.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Momentum Rank for a Medical Devices & Instruments company?
A good Momentum Rank depends on the Medical Devices & Instruments industry context. However, Momentum Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Momentum Rank mean?
A high Momentum Rank can signal that a stock is expensive relative to its fundamentals. Momentum Rank is determined using the standardized momentum ratio, measuring the speed and velocity of price changes in a stock. View historical data on Integra Lifesciences Holdings and its competitors. Integra Lifesciences Holdings's current Momentum Rank is 9, which is 29% above median its own 10-year median of 7.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Integra Lifesciences Holdings stock overvalued right now?
Based on GuruFocus' analysis, Integra Lifesciences Holdings (IART) is currently considered Modestly Undervalued. The stock's GF Value™ is $20.52, compared to a current price of $16.69 — trading 18.7% below its estimated fair value. The current Momentum Rank is 9, which is 29% above median its 10-year median of 7.00. Integra Lifesciences Holdings' overall GF Score™ is 70/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Momentum Rank calculated?
Momentum Rank is calculated from a company's financial statements. For Integra Lifesciences Holdings (IART), the current Momentum Rank is 9 as of Aug. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Integra Lifesciences Holdings (IART) Overvalued in 2026?

Based on GuruFocus' analysis, Integra Lifesciences Holdings stock appears to be undervalued. The current stock price of $16.69 is trading 18.7% below its estimated GF Value™ of $20.52. GuruFocus considers Integra Lifesciences Holdings to be Modestly Undervalued.

Key valuation signals for IART:

  • Momentum Rank: 9 (29% above median its 10-year median of 7.00)
  • GF Value™: $20.52 vs. price of $16.69 (18.7% below fair value)
  • GF Score™: 70/100 with 8 warning signs

No single metric tells the full story. See the IART stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Integra Lifesciences Holdings Business Description

Other Exchanges IL3:Germany
Address 1100 Campus Road, Princeton, NJ, USA, 08540
Integra Lifesciences Holdings Corp is a New Jersey-based medical equipment company focused on developing products for regenerative therapy, extremity orthopedics, and neurosurgical applications. The firm is organized into two primary segments: Codman specialty surgical and Tissue technologies. Codman Specialty Surgical generates maximum revenue from its segmental operations. Integra serves Europe, Asia Pacific, and the rest of the world whilst it derives key revenue from domestic sales. The company operates in United States, Europe, Asia Pacific, and Rest of the World.
70GF Score

Get the complete analysis for IART

Momentum Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$16.69
Price
$20.52
GF Value